Allogene Therapeutics (ALLO) Cash from Investing Activities (2018 - 2026)

Allogene Therapeutics has disclosed Cash from Investing Activities across 9 years of filings, most recently posting -$29.6 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$29.6 million, down 579.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $59.8 million (changed 0.11% YoY), and the FY2025 annual result was $95.6 million, up 26.25% from the prior year.
• Cash from Investing Activities came in at -$29.6 million for Q1 2026 at Allogene Therapeutics, down from $33.6 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $112.9 million in Q1 2023 to a low of -$76.0 million in Q3 2024.
• The 5-year median for Cash from Investing Activities is $24.9 million (2022), against an average of $24.2 million.
• Across the five-year window, Cash from Investing Activities soared 604.69% in 2023 and plunged 579.08% in 2026, its largest moves.
• Allogene Therapeutics' Cash from Investing Activities stood at $49.6 million in 2022, then jumped by 36.02% to $67.5 million in 2023, then declined by 18.57% to $54.9 million in 2024, then plunged by 38.81% to $33.6 million in 2025, then slumped by 188.03% to -$29.6 million in 2026.
• The last three Cash from Investing Activities figures came in at -$29.6 million (Q1 2026), $33.6 million (Q4 2025), and $11.9 million (Q3 2025), per Business Quant data.